Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHATIL-102
- Development stage
- Unknown
- Lead developer
- CHA
- Modality
- Cell Therapies
01
Overview
CHATIL-102 is an autologous tumor-infiltrating lymphocyte cell therapy being developed by CHA for solid tumors, with the company pipeline specifically listing head and neck cancer and gynecologic cancers. It is an adoptive cell therapy intended to expand and reinfuse tumor-reactive T cells isolated from a patient's own tumor in order to mediate anti-tumor immune responses. Available company context indicates this is a next-generation TIL program under Korea's Advanced Regenerative Bio Act clinical research and early access framework, corresponding to early clinical development.
- Other names
- CHA autologous TIL cell therapy
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on CHATIL-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHATIL-102.